BridgeBio Pharma (BBIO) Cash from Investing Activities (2018 - 2026)

BridgeBio Pharma has reported Cash from Investing Activities for 9 years, with the latest figure at -$42.7 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 2579.31% year-over-year to -$42.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$65.6 million (down 280.13% YoY) and the FY2025 annual result came in at -$24.5 million, down 140.29% from the prior year.
• Cash from Investing Activities slipped to -$42.7 million in Q1 2026 per BBIO's latest filing, from -$14.4 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $149.7 million in Q2 2022 and troughed at -$42.7 million in Q1 2026.
• A 5-year average of $29.5 million and a median of $4.5 million in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities surged 32586.03% in 2022, then slumped 4804.55% in 2024.
• Over 5 years, Cash from Investing Activities stood at $18.0 million in 2022, then tumbled by 100.37% to -$66000.0 in 2023, then plunged by 4804.55% to -$3.2 million in 2024, then plunged by 343.44% to -$14.4 million in 2025, then tumbled by 197.72% to -$42.7 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$42.7 million, -$14.4 million, and $4.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.